Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00163501 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT00163501 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 600 participants.
The verdict
NCT00163501, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.
Interventions
- DRUG Ciclesonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00163501
The ClinicalTrials.gov registry entry for NCT00163501 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ciclesonide is the first listed.
NCT00163501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00163501 about?
NCT00163501 is a clinical study titled "Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)". The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.
What is the current status of trial NCT00163501?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2003-12. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00163501?
The interventions under investigation include: Ciclesonide (DRUG).
Who is sponsoring clinical trial NCT00163501?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.